当前位置: X-MOL 学术Nat. Rev. Drug. Disc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fiona Marshall
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2018-02-28 , DOI: 10.1038/nrd.2018.25


Fiona Marshall

Fiona Marshall, Published online: 28 February 2018; doi:10.1038/nrd.2018.25

Fiona Marshall — co-founder of Heptares, former chief scientific officer of Sosei and soon to be lead of Merck & Co.'s new research facility in London — looks back on 30 years of GPCRs, and looks forward to the emerging therapeutic opportunities these targets still offer.


中文翻译:

菲奥娜·马歇尔(Fiona Marshall)

菲奥娜·马歇尔(Fiona Marshall)

菲奥娜·马歇尔(Fiona Marshall),在线发布:2018年2月28日; doi:10.1038 / nrd.2018.25

菲奥娜·马歇尔(Fiona Marshall)是赫普塔雷斯(Heptares)的联合创始人,曾任Sosei公司首席科学官,不久将成为默克公司(Merck&Co.)在伦敦的新研究机构的负责人–回顾了30年的GPCR,并期待着这些新的治疗机会目标仍然提供。
更新日期:2018-02-28
down
wechat
bug